Adaptimmune Therapeutics plc logo
Adaptimmune Therapeutics plc ADAP
$ 0.64 -3.05%

Quarterly report 2024-Q3
added 11-13-2024

report update icon

Adaptimmune Therapeutics plc Balance Sheet 2011-2024 | ADAP

Annual Balance Sheet Adaptimmune Therapeutics plc

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-119 M -85 M -126 M -37.8 M -11.3 M 68.4 M 40.2 M -159 M -186 M -51.3 M 1.29 M -3.02 M -

Long Term Debt

19.9 M 20.3 M 23.1 M 20.9 M 23 M - - - - - - - -

Long Term Debt Current

5.38 M 2.73 M 2.32 M 2.77 M 2.49 M - - - - - - - -

Total Non Current Liabilities

- - - - 23.6 M 5.41 M 3.85 M 28.1 M 11.6 M - - - -

Total Current Liabilities

72.8 M 64.5 M 62.5 M 39.1 M 34.3 M 24.4 M 74.3 M 40.3 M 27.9 M - - - -

Total Liabilities

243 M 247 M 264 M 110 M 57.9 M 29.9 M 78.2 M 68.4 M 33.4 M 53.1 M 3.97 M 4.09 M -

Deferred Revenue

29 M 23.5 M 22.2 M 2.83 M 2.13 M - 38.7 M 11.4 M - - - - -

Retained Earnings

-1.02 B -909 M -744 M -586 M -456 M -318 M -232 M -161 M -38.3 M -32.3 M -17.6 M -9.66 M -

Total Assets

283 M 329 M 470 M 451 M 182 M 277 M 281 M 235 M 244 M 55.5 M 1.81 M 3.96 M -

Cash and Cash Equivalents

144 M 108 M 152 M 61.5 M 50.4 M 68.4 M 84 M 159 M 194 M - - - -

Book Value

39.5 M 81.9 M 206 M 341 M 124 M 247 M 203 M 166 M 211 M 2.41 M -2.16 M -126 K -

Total Shareholders Equity

39.5 M 81.9 M 206 M 341 M 124 M 247 M 203 M 166 M 235 M 2.96 M -2.16 M - -

All numbers in USD currency

Quarterly Balance Sheet Adaptimmune Therapeutics plc

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

49.9 M 25 M 18.4 M 19.9 M 20.5 M 21.6 M 20 M 20.3 M 19.9 M - 23.2 M 23.1 M 23.7 M 19.7 M 19.9 M 20.9 M 20.9 M 20.9 M 20.9 M 23 M 23 M 23 M 23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

237 M 225 M 234 M 243 M 209 M 216 M 204 M 247 M 219 M - 257 M 264 M 113 M 112 M 102 M 110 M 110 M 110 M 110 M 57.9 M 57.9 M 57.9 M 57.9 M 29.9 M 29.9 M 29.9 M 29.9 M 78.2 M 78.2 M 78.2 M 78.2 M 68.4 M 68.4 M 68.4 M 42.6 M 50.8 M 50.8 M 50.8 M 50.8 M - - 52.8 M - - - - - - - - - - - - -

Deferred Revenue

18.7 M 38.4 M 31.5 M 29 M 29.3 M 31.4 M 22.3 M 23.5 M 20.6 M - 24.8 M 22.2 M 6.1 M 4.91 M 2.08 M 2.83 M 2.83 M 2.83 M 2.83 M 2.13 M 2.13 M 2.13 M 2.13 M - 1.34 M 16.7 M 27.2 M 38.7 M 42.6 M 12.3 M 11.6 M 11.4 M 11.4 M 11.4 M 12.1 M 12.5 M 12.5 M 12.5 M 12.5 M - - 41.8 M - - - - - - - - - - - - -

Retained Earnings

-1.02 B -1 B -1.07 B -1.02 B -975 M -930 M -908 M -909 M -880 M - -794 M -744 M -705 M -663 M -624 M -586 M -586 M -586 M -586 M -456 M -456 M -456 M -456 M -318 M -318 M -318 M -318 M -232 M -232 M -232 M -232 M -161 M -161 M -161 M -105 M -89.9 M -89.9 M -89.9 M -89.9 M - - -30.1 M - - - - - - - - - - - - -

Total Assets

317 M 322 M 258 M 283 M 297 M 343 M 288 M 329 M 332 M - 420 M 470 M 354 M 390 M 412 M 451 M 451 M 451 M 451 M 182 M 182 M 182 M 182 M 277 M 277 M 277 M 277 M 281 M 281 M 281 M 281 M 235 M 235 M 235 M 262 M 286 M 286 M 286 M 286 M - - 55.7 M - - - - - - - - - - - - -

Cash and Cash Equivalents

117 M 212 M 141 M 144 M 93.1 M 80.2 M 121 M 108 M 80.7 M 99.5 M 91.3 M 150 M 44.6 M 50.5 M 32.4 M 56.9 M 56.9 M 56.9 M 56.9 M 50.4 M 50.4 M 50.4 M 50.4 M 68.4 M 68.4 M 68.4 M 68.4 M 84 M 84 M 84 M 84 M 159 M 159 M 159 M 164 M 194 M 194 M 194 M 194 M 102 M - 51.2 M - - - - - - - 3.11 M - - - - -

Book Value

80 M 96.3 M 24.4 M 39.5 M 88.1 M 127 M 83.9 M 81.9 M 113 M - 163 M 206 M 241 M 278 M 309 M 341 M 341 M 341 M 341 M 124 M 124 M 124 M 124 M 247 M 247 M 247 M 247 M 203 M 203 M 203 M 203 M 166 M 166 M 166 M 219 M 235 M 235 M 235 M 235 M - - 2.96 M - - - - - - - - - - - - -

Total Shareholders Equity

80 M 96.3 M 24.4 M 39.5 M 88.1 M 127 M 83.9 M 81.9 M 113 M 142 M 163 M 206 M 241 M 278 M 309 M 341 M 341 M 341 M 341 M 124 M 124 M 124 M 124 M 247 M 276 M 247 M 247 M 203 M 229 M 229 M 208 M 166 M 166 M 166 M 219 M 235 M 235 M 235 M 235 M - - 2.96 M - - - -2.16 M - - - -124 K - - - - -

All numbers in USD currency